Free Trial
→ Here’s How to Claim Your Stake in Elon’s Private Company, xAI (From Brownstone Research) (Ad)

Enfusion Q2 2023 Earnings Report

Enfusion logo
$11.02 -0.13 (-1.12%)
As of 03:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Earnings HistoryForecast

Enfusion EPS Results

Actual EPS
$0.02
Consensus EPS
$0.02
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Enfusion Revenue Results

Actual Revenue
$42.72 million
Expected Revenue
$44.58 million
Beat/Miss
Missed by -$1.86 million
YoY Revenue Growth
N/A

Enfusion Announcement Details

Quarter
Q2 2023
Date
8/8/2023
Time
N/A

Conference Call Resources

Conference Call Audio

Powered by Quartr
Remove Ads

Enfusion Earnings Headlines

Clearwater Analytics and Enfusion Announce Election Deadline for Enfusion Shareholders to Elect Form of Merger Consideration
April 2 at 5:01 PM | businesswire.com
ENFUSION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Enfusion, Inc. - ENFN
April 2 at 12:32 PM | businesswire.com
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
April 3, 2025 | American Alternative (Ad)
Enfusion, Inc.: Enfusion Announces Fourth Quarter and Full Year 2024 Results
March 4, 2025 | finanznachrichten.de
Enfusion Announces Fourth Quarter and Full Year 2024 Results
March 3, 2025 | businesswire.com
Clearwater Analytics and Enfusion Announce Expiration of Hart-Scott-Rodino Act Waiting Period For Proposed Acquisition of Enfusion
February 26, 2025 | businesswire.com
See More Enfusion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enfusion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enfusion and other key companies, straight to your email.

About Enfusion

Enfusion (NYSE:ENFN) provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.

View Enfusion Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles